Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
12:29pm, Thursday, 30'th Nov 2023
Other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.
AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio
12:16pm, Thursday, 30'th Nov 2023
ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie (ABBV) agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.
AbbVie to Acquire ImmunoGen in $10 Billion Deal
08:18am, Thursday, 30'th Nov 2023
AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share.
AbbVie Should Consider a Dividend Cut -- Here's Why
08:15am, Thursday, 30'th Nov 2023
AbbVie has consistently been one of the best-performing Dividend Kings over the past 10 years. With its flagship drug in decline, however, the company's shares have faltered in 2023.
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
07:46am, Thursday, 30'th Nov 2023
AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market for cancer treatments.
AbbVie $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium
07:43am, Thursday, 30'th Nov 2023
AbbVie Inc. ABBV, +0.30% announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN, +0.50% in a cash deal valued at $10.1 billion. Under terms of the agreement, AbbVie will
AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)
11:45pm, Wednesday, 29'th Nov 2023
A proven track record of putting shareholders first is part of the litmus test that I use before buying stocks. AbbVie's recent 4.7% dividend hike builds on an impressive dividend growth streak that i
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today's Economy
06:47pm, Wednesday, 29'th Nov 2023
Blue chip stocks are generally a strong investment for any stage of the economic cycle and tend to take advantage of overarching trends. That remains as true today as it was yesterday and will be tom
Why I Made Big Changes To My Dividend Growth Portfolio
11:25am, Wednesday, 29'th Nov 2023
I've made significant changes to my portfolio due to buying a new house and selling stocks from my portfolio to raise cash. My goal is to prioritize building a passive income stream, but I recognize t
4 Large Drug Stocks to Watch as IBD Market Gains Traction
11:20am, Wednesday, 29'th Nov 2023
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024
11:10am, Wednesday, 29'th Nov 2023
Value stocks have underperformed since 2006. However, I expect a shift in market dynamics, particularly for healthcare stocks. AbbVie is a compelling value play with a 4.5% yield, strong performance,
These are the top sectors for blue chip growth in 2024
09:05am, Wednesday, 29'th Nov 2023
With 2023 drawing to a close, it's time to start looking at 2024 and what it may bring to investors. The number one item on the list is uncertainty.
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
12:47pm, Tuesday, 28'th Nov 2023
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.
Buy 6 December Dividend Kings, 4 More On Watch
07:53am, Monday, 27'th Nov 2023
"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years." - Dogs of th
AbbVie says FDA has granted breakthrough therapy designation to epocritamab for a type of lymphoma
07:16am, Monday, 27'th Nov 2023
AbbVie Inc. ABBV said Monday the U.S. Food and Drug Administration has granted breakthrough therapy designation, or BTD, to its epocritamab treatment for relapsed or refractory (R/R) follicular lympho
